Skip to main content
R

Releviate

This company develops human monoclonal antibody therapies to treat neuropathic pain by targeting and inactivating specific matrix metalloproteinases. Their approach offers an alternative to opioids by addressing the underlying causes of chronic pain.

Updated 2 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Features

  • This company develops human monoclonal antibody therapies to treat neuropathic pain by targeting and inactivating specific matrix metalloproteinases. Their approach offers an alternative to opioids by addressing the underlying causes of chronic pain.
This profile is AI-generated and may contain inaccuracies.